L Capital Partners

The El Ganso style is composed of a cosmopolitan look tinged with Spanish colours and ranges from preppy American looks to the more alternative Berlin style, via a touch of English elegance. Its signature, classic and cheeky, has become the main emblem of the brand, an inspiration that can be observed in the optimism of its garments, footwear and accessories. The originality and strength of its designs can be easily recognized in the taste for details and fabrics. Every collection is designed and manufactured 100% within Europe from local raw materials in accordance with the company’s main priorities of design, quality and innovation.

Vicini develops and manufactures footwear for men and women. The company sells its products through its Milan and New York showrooms to a selected clientele, and to its boutiques. It also offers its products through stores in Europe, Russia, Asia, and Australia.

Cigierre is engaged in the development, operation, and management of multiethnic restaurants. The company operates and franchises a diverse range of dining establishments, including burger and steak houses, pizzerias, and restaurants offering both oriental and American cuisine. Located primarily in Italy, Cigierre aims to provide a blend of innovative and traditional dishes in a casual dining environment, focusing on customer-oriented service and a varied menu that caters to different tastes. Through its commitment to quality and variety, the company enhances the dining experience for its visitors.

IntraPace, Inc. is a medical device company focused on developing innovative solutions for obesity treatment. Founded in 2001 and headquartered in Mountain View, California, the company has created the abiliti system, an implantable device that stimulates a satiety response to assist patients in achieving weight loss. This device utilizes established technology similar to that found in cardiac pacemakers and defibrillators. The abiliti system is designed for implantation using standard laparoscopic techniques, allowing for a minimally invasive procedure that does not alter the anatomy of the digestive system or restrict dietary choices.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

WiSpry, Inc. is a fabless radio frequency (RF) semiconductor company based in Irvine, California, founded in 2002. The company develops and markets RF silicon integrated circuits, components, and modules designed for wireless communication products. WiSpry's offerings include tunable RF components, digital capacitor arrays, RF evaluation kits, filters, duplexors, and power amplifiers. These products are utilized in a wide range of applications, such as airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. The company primarily serves mobile handset manufacturers, RF module manufacturers, cellular base station suppliers, and various original equipment manufacturers (OEMs) in the electronics sector. In 2015, WiSpry became a subsidiary of AAC Technologies Holdings Inc.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Evogen, Inc. is a diagnostics company specializing in technologies for the detection of chemical and biological pathogens that pose risks to human and animal health. The company develops high definition polymerase chain reaction (HD PCR) molecular diagnostics systems, as well as HyBeacons PCR for pathogen detection and DryClone for collecting biological pathogens and low vapor particulates. Additionally, Evogen offers SpinCon, a portable air sampler designed for collecting bioaerosols, particulate matter, and soluble vapors, along with evoPrep for DNA extraction. Its solutions cater to a variety of sectors, including safety and security, clinical and laboratory services, research, and environmental monitoring. Founded in 2001 as Sceptor Industries, Inc., the company rebranded to Evogen, Inc. in 2008 and is headquartered in Lenexa, Kansas.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

Eleme Medical, Inc. is a venture-backed aesthetics company specializing in advanced technologies for body shaping. The company has developed the SmoothShapes® product line, including the recently launched SmoothShapes® XV, which aims to transform cellulite treatment and enhance pre- and post-liposuction care. This innovative device features 50% more laser power and incorporates audible and visual treatment guidance, all within a portable design, making it suitable for various medical practices. Both SmoothShapes systems leverage the proprietary Photomology® platform, which combines dynamic light and laser energy with mechanical manipulation to effectively address cellulite and subcutaneous fat. These CE Marked and FDA-cleared medical devices are designed to provide long-lasting results that improve the appearance of cellulite. Eleme Medical targets plastic surgeons, aesthetic dermatologists, medical spas, and other aesthetic physicians, positioning itself within a rapidly growing segment of the aesthetics market.

Exenta Inc. develops software tailored for the fashion and consumer goods industries, offering solutions that encompass enterprise resource planning (ERP), product lifecycle management (PLM), and shop floor control. Founded in 2007 and based in New York, the company provides tools for supply chain management, materials planning, and inventory management, enabling brands and manufacturers to optimize their operations. Exenta's software supports real-time data collection, workforce performance tracking, and quality control, facilitating efficient management of design processes and seasonal product lines. With a focus on flexibility, Exenta addresses the dynamic needs of its clients, offering services in multiple languages and currencies. The company serves over 41,000 users across 15 countries, aiming to be a comprehensive solution partner for businesses at all stages of growth.

WiSpry, Inc. is a fabless radio frequency (RF) semiconductor company based in Irvine, California, founded in 2002. The company develops and markets RF silicon integrated circuits, components, and modules designed for wireless communication products. WiSpry's offerings include tunable RF components, digital capacitor arrays, RF evaluation kits, filters, duplexors, and power amplifiers. These products are utilized in a wide range of applications, such as airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. The company primarily serves mobile handset manufacturers, RF module manufacturers, cellular base station suppliers, and various original equipment manufacturers (OEMs) in the electronics sector. In 2015, WiSpry became a subsidiary of AAC Technologies Holdings Inc.

Hi-G-Tek, Inc. specializes in developing and providing wireless solutions for real-time location tracking, security, and condition monitoring of high-value and sensitive cargo and assets. Founded in 1989 and based in Rockville, Maryland, the company offers a range of products, including tanker truck monitoring systems, cargo tracking solutions, and an enterprise services platform that processes data from various sensing devices. Hi-G-Tek's technology enables effective monitoring and securing of assets, whether stationary or in transit, and is particularly beneficial for industries such as fuel distribution, military logistics, and hazardous materials management. The company also produces electronic locks, seals, tags, and the necessary hardware to support its monitoring solutions. Hi-G-Tek markets its products through authorized distributors both in the United States and internationally, serving a diverse clientele that includes private enterprises and government agencies.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

IntelliPath Solutions provides Information Management consulting services to companies who leverage data as an asset of their organization. IntelliPath’s industry experience in both IT and business, in combination with our ability to align innovation and best practices, allows for successful partnerships with our clients.

Locus Pharmaceuticals, Inc. develops a drug design and development platform for oral drug therapies in the areas of unmet medical needs. Its fragment-based computational drug design technology is used for the discovery and development of compounds for the treatment of unmet medical needs. The company has a computational drug design technology, which is used to develop a pipeline of drug development candidates, including direct and allosteric kinase inhibitors for cancer and inflammation diseases. Locus Pharmaceuticals, Inc. was formerly known as Locus Discovery, Inc. The company was incorporated in 1998 and is based in Blue Bell, Pennsylvania. Locus Pharmaceuticals, Inc. is a former subsidiary of Sarnoff Corporation.

WiSpry, Inc. is a fabless radio frequency (RF) semiconductor company based in Irvine, California, founded in 2002. The company develops and markets RF silicon integrated circuits, components, and modules designed for wireless communication products. WiSpry's offerings include tunable RF components, digital capacitor arrays, RF evaluation kits, filters, duplexors, and power amplifiers. These products are utilized in a wide range of applications, such as airbag sensors, game controllers, accelerometers, microoptics, video projection systems, and printer heads. The company primarily serves mobile handset manufacturers, RF module manufacturers, cellular base station suppliers, and various original equipment manufacturers (OEMs) in the electronics sector. In 2015, WiSpry became a subsidiary of AAC Technologies Holdings Inc.

Hi-G-Tek, Inc. specializes in developing and providing wireless solutions for real-time location tracking, security, and condition monitoring of high-value and sensitive cargo and assets. Founded in 1989 and based in Rockville, Maryland, the company offers a range of products, including tanker truck monitoring systems, cargo tracking solutions, and an enterprise services platform that processes data from various sensing devices. Hi-G-Tek's technology enables effective monitoring and securing of assets, whether stationary or in transit, and is particularly beneficial for industries such as fuel distribution, military logistics, and hazardous materials management. The company also produces electronic locks, seals, tags, and the necessary hardware to support its monitoring solutions. Hi-G-Tek markets its products through authorized distributors both in the United States and internationally, serving a diverse clientele that includes private enterprises and government agencies.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.

Tengion is a clinical-stage biotechnology company focused on developing neo-organs and neo-tissues derived from a patient's own cells. The company has made significant advancements in regenerative medicine, particularly with its Tengion Neo-Bladder Augment, which has undergone two Phase 2 human clinical trials in the United States for treating neurogenic bladder conditions in both children and adults. Additionally, Tengion is preparing to initiate a Phase 1 clinical trial for its Neo-Urinary Conduit, aimed at bladder cancer patients who require bladder removal. The company's innovative approach seeks to eliminate the need for donor organs and reduce reliance on anti-rejection medications by creating living tissue products that can regenerate or replace damaged organs.

Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.